Literature DB >> 17007278

[Thrombinogenesis in chronic myeloproliferative syndromes].

Danuta Rość1, Elzbieta Kremplewska-Nalezyta, Grazyna Gadomska, Anita Kowalewska, Elzbieta Buczkowska.   

Abstract

UNLABELLED: Haemostatic disturbances are important in clinical complications in patients with chronic myeloproliferative syndromes and sometimes the reason of death. Pathogenesis of thrombo-embolic disease during these states is not clear. The aim of study was the evaluation of the risk of thrombosis in patients with chronic myeloproliferative syndromes using very detailed test to measure the concentration of TAT (thrombin-antithrombin) complexes.
MATERIAL AND METHODS: The study was performed in 73 patients: in 22 with chronic myeloid leucaemia (CML), in 25 with polycythemia vera (PV), in 21 with essential thrombocytemia (ET) and in 5 with myelofibrosis (MF). The control group consisted of 29 healthy volunteers. In the blood plasma of studied persons concentration of TAT complexes and antithrombin (AT) activity were detected.
RESULTS: We observed in patients, except MF, significant increase of TAT but diminished AT activity.
CONCLUSIONS: Increased TAT complexes in chronic myeloproliferative syndromes is the evidence of significant thrombinogenesis. AT activity diminished in PV showes too high consumption of it with concomitant low synthesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17007278

Source DB:  PubMed          Journal:  Pol Merkur Lekarski        ISSN: 1426-9686


  1 in total

1.  Circulating endothelial cells in essential thrombocythemia and polycythemia vera: correlation with JAK2-V617F mutational status, angiogenic factors and coagulation activation markers.

Authors:  Jacek Treliński; Agnieszka Wierzbowska; Anna Krawczyńska; Agata Sakowicz; Tadeusz Pietrucha; Piotr Smolewski; Tadeusz Robak; Krzysztof Chojnowski
Journal:  Int J Hematol       Date:  2010-05-15       Impact factor: 2.490

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.